Skip to content Skip to footer
AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…
Week ending Friday, August 7, 2026 — U.S. equities finished the week decisively higher, led by technology and smaller-capitalization shares. The market’s message was nuanced: economic activity indicators remained firm, but July’s unexpected payroll decline reinforced the view that the labor market…